NCT03712423 is a Phase 1 clinical trial of Cripec Docetaxel in Solid Tumor, sponsored by Amsterdam UMC, location VUmc.

Who is sponsoring NCT03712423?

NCT03712423 is sponsored by Amsterdam UMC, location VUmc.

What drugs are being tested in NCT03712423?

Interventions in NCT03712423: Cripec Docetaxel.

What condition does NCT03712423 study?

NCT03712423 studies Solid Tumor.

Is NCT03712423 still recruiting?

NCT03712423 is currently completed. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT03712423

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PET Study With [89Zr]-Df-CriPec® Docetaxel

Completed Phase 1 Last updated 8 October 2020

What this trial tests

Phase 1 trial testing Cripec Docetaxel in Solid Tumor in 7 participants. Completed in 8 May 2020.

Timeline

1 April 2018

Primary endpoint
25 March 2020

8 May 2020

Quick facts

Lead sponsor	Amsterdam UMC, location VUmc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	1 April 2018
Primary completion	25 March 2020
Estimated completion	8 May 2020
Sites	1 location across Netherlands

Drugs / interventions tested

Cripec Docetaxel — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Amsterdam UMC, location VUmc — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A clinical phase I, open-label PET study with \[89Zr\]-Df-CriPec® docetaxel in patients with solid tumours to assess biodistribution and tumour accumulation of \[89Zr\]-Df-CriPec® docetaxel.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Nanoparticles in the clinic: An update.
Anselmo AC, Mitragotri S. · · 2019 · cited 976× · PMID 31572799 · DOI 10.1002/btm2.10143
Polymeric Nanoparticles for Drug Delivery.
Beach MA, Nayanathara U, Gao Y, Zhang C, et al · · 2024 · cited 476× · PMID 38626459 · DOI 10.1021/acs.chemrev.3c00705
Smart nanoparticles for cancer therapy.
Sun L, Liu H, Ye Y, Lei Y, et al · · 2023 · cited 474× · PMID 37919282 · DOI 10.1038/s41392-023-01642-x
Nanoparticles in the clinic: An update post COVID-19 vaccines.
Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246
New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.
Gawne PJ, Ferreira M, Papaluca M, Grimm J, et al · · 2023 · cited 112× · PMID 39022623 · DOI 10.1038/s41578-023-00581-x
Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems.
Silva CO, Pinho JO, Lopes JM, Almeida AJ, et al · · 2019 · cited 101× · PMID 30625999 · DOI 10.3390/pharmaceutics11010022
Polymeric Micellar Systems-A Special Emphasis on "Smart" Drug Delivery.
Negut I, Bita B. · · 2023 · cited 66× · PMID 36986837 · DOI 10.3390/pharmaceutics15030976
Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use.
Dhupal M, Chowdhury D. · · 2020 · cited 48× · PMID 33244231 · DOI 10.2147/ijn.s259628

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Amsterdam UMC, location VUmc trials

Trials by the same sponsor.

NCT07470697 — Deep Relaxation Using Virtual Reality Intervention Before Surgery for Healthcare Professionals Working in the Operating · NA · not yet recruiting
NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting
NCT07155681 — Evaluating Healthcare Professionals' Satisfaction and Stress Mitigation Using Virtual Reality Intervention in Surgical W · NA · not yet recruiting
NCT06416345 — Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care · NA · recruiting
NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03712423 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amsterdam UMC, location VUmc
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03712423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing